Ramipril Tablets IP/ – Manufacturer India

1. Product Introduction

Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer of Ramipril Tablets IP 2.5 mg and 5 mg, with Healthy Inc identified as exporter. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor used for hypertension, selected heart failure indications, and cardiovascular risk reduction in appropriate high-risk patients.

Ramipril is sensitive to moisture and manufacturing stress, so validated processing, stability assessment and suitable protective packaging are important. Contract manufacturing, certification, export territories and available capacity should be confirmed with the company.

2. Product Specifications

3. Manufacturing Technology

Stability considerations: Ramipril may degrade through hydrolysis and intramolecular cyclization. Manufacturing should control moisture exposure, temperature, excipient compatibility and mechanical stress according to validated process parameters.

Uniformity and coating: Low-dose tablets require validated blending and content-uniformity controls. Film-coating and packaging must meet approved dissolution and stability specifications.

Export packaging: Moisture-barrier packaging may be appropriate where supported by product stability studies. Claims about specific humidity limits, equipment, exclusive Alu-Alu packaging or manufacturing methods require documentary confirmation.

4. Quality Assurance

Each released batch should meet the applicable approved Indian Pharmacopoeia specification and marketing authorization requirements.

• Identity and assay: Verify the active ingredient and labeled potency using validated analytical methods.
• Related substances: Monitor specified ramipril degradation products, including diketopiperazine-related impurities, against approved limits.
• Dissolution and uniformity: Confirm tablet performance and dose consistency.
• Stability: Use approved studies to establish packaging and shelf life.

Exact acceptance limits must be taken from the applicable current monograph and registered specification, not assumed universal values.

5. Mechanism and Therapeutic Uses

Ramipril inhibits angiotensin-converting enzyme, reducing formation of angiotensin II and lowering aldosterone activity. This promotes vasodilation and can reduce blood pressure and cardiac workload.

• Hypertension: Treatment of elevated blood pressure.
• Heart failure: Used in selected patients, including certain patients following myocardial infarction.
• Cardiovascular risk reduction: May reduce the risk of major cardiovascular events in appropriately selected high-risk patients.
• Kidney protection: May reduce proteinuria in some patients, but kidney function and potassium require monitoring.

Indications depend on the locally approved label and clinical assessment.

6. Export and Regulatory Support

For B2B enquiries, request the current product license, approved specifications, batch certificate of analysis, packaging configuration, stability information and available registration documents.

CTD/ACTD dossiers, Free Sale Certificates, COPP, WHO-GMP evidence, shipping terms and export-market approvals should be confirmed for the particular product and destination before publication or tender submission.

7. Frequently Asked Questions

Q: Which Ramipril strengths are specified?
A: Film-coated IP 2.5 mg and 5 mg tablets. Other strengths require availability confirmation.

Q: Why can ramipril cause a dry cough?
A: ACE inhibition can increase bradykinin and related mediators. Persistent cough should be discussed with a clinician.

Q: Does ramipril protect the kidneys?
A: It may benefit selected patients with proteinuric kidney disease, but it can also raise potassium or worsen kidney function in certain circumstances. Monitoring is essential.

Q: Can it be taken during pregnancy?
A: No. ACE inhibitors can harm the fetus. A patient who becomes pregnant should contact their clinician promptly for alternative treatment.

8. Dosage and Administration

Ramipril dose and titration depend on indication, blood pressure, renal function, other medicines and patient tolerance. Prescribers may start with a low dose and adjust under monitoring; the 2.5 mg and 5 mg tablets are not interchangeable without an appropriate prescription.

Take orally as directed by the prescriber, with or without food according to the approved label. Do not stop or change the dose without medical advice. Monitor blood pressure, kidney function and serum potassium when starting therapy and after relevant dose changes.

9. Side Effects and Precautions

• Common: Dry cough, dizziness and low blood pressure, particularly when initiating treatment.
• Serious: Angioedema (swelling of face, lips, tongue or throat) requires emergency medical attention; discontinue and seek urgent care.
• Potassium and kidneys: Hyperkalemia and changes in renal function may occur. Caution with potassium supplements, potassium-sparing medicines, NSAIDs and dehydration.
• Pregnancy: Contraindicated due to risk of fetal injury and death.
• Interactions: Avoid use with sacubitril/valsartan within the required washout interval; other ACE inhibitor contraindications and interactions must be reviewed by a clinician.

10. Storage Instructions

Store according to the approved product label, protected from moisture and excessive heat. Keep tablets in their original protective packaging until use where specified. The proposed below-25°C storage condition must be confirmed against the registered label and stability data.

Keep out of reach of children.